E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hepatitis C Virus Infection |
Infección por el virus de la hepatitis C |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019744 |
E.1.2 | Term | Hepatitis C |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10021881 |
E.1.2 | Term | Infections and infestations |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the durability of SVR; To assess clinical progression or regression of liver disease, including the incidence of hepatocellular carcinoma (HCC) following SVR. |
Evaluar la durabilidad de la RVS; evaluar la progresión o regresión clínicas de la enfermedad hepática, incluida la incidencia de carcinoma hepatocelular (CHC) después de la RVS. |
|
E.2.2 | Secondary objectives of the trial |
To determine whether subsequent detection of HCV RNA in subjects who relapse following SVR represents the re-emergence of pre-existing virus, the development of resistance mutations, or re-infection.
To assess quality of life following SVR. |
Determinar si la posterior detección de ARN del VHC en sujetos que presenten recidiva después de la RVS supone la reaparición del virus preexistente, el desarrollo de mutaciones de resistencia o una nueva infección.
Evaluar la calidad de vida después de la RVS. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Willing and able to provide written informed consent; 2) Have previously participated in a Gilead-sponsored HCV study and received a sofosbuvir-containing regimen without interferon; 3) Have achieved SVR in a Gilead-sponsored study, as defined in the treatment protocol; 4) Have liver cirrhosis, as defined in the treatment protocol, and have not had a liver transplant after receiving a SOF-containing regimen. |
1) Ser capaces de y estar dispuestos a otorgar su consentimiento informado por escrito; 2) Haber participado previamente en un estudio de VHC promovido por Gilead y haber recibido un régimen que contuviera sofosbuvir sin interferón; 3) Haber conseguido en un estudio promovido por Gilead una RVS, según la definición del protocolo de tratamiento; 4) Tener cirrosis hepática, según la definición del protocolo de tratamiento, y no haberse sometido a un trasplante de hígado después de recibir el régimen con SOF. |
|
E.4 | Principal exclusion criteria |
1) Subject plans to initiate a new course of HCV therapy, including approved products and any investigational agents, during the course of this Registry; 2) History of clinically-significant illness or any other major medical disorder that may interfere with the subject follow-up, assessments or compliance with the protocol. |
1) El sujeto tiene previsto iniciar, durante el transcurso de este registro, un nuevo curso de tratamiento para el VHC, lo que incluye productos aprobados y cualquier agente en fase de investigación; 2) Tener antecedentes de una enfermedad clínicamente significativa o de cualquier otro trastorno médico importante que pudieran interferir con el seguimiento del sujeto, las evaluaciones o el cumplimiento del protocolo. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
To assess the durability of SVR;
To assess clinical progression or regression of liver disease, including the incidence of hepatocellular carcinoma (HCC) following SVR. |
Evaluar la durabilidad de la RVS;
Evaluar la progresión o regresión clínicas de la enfermedad hepática, incluida la incidencia de carcinoma hepatocelular (CHC) después de la RVS. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The proportion of subjects maintaining SVR at Week 240;
The proportion of subjects who develop liver disease progression or regression, as assessed by clinical and laboratory parameters throughout the study;
The proportion of subjects who develop HCC through Week 240. |
La proporción de sujetos que mantengan una RVS hasta la semana 240;
La proporción de sujetos que presenten una evolución de la enfermedad hepática o regresión, evaluada por parametros clínicos y de laboratorio durante todo el estudio;
La proporción de sujetos que desarrollen CHC hasta la semana 240. |
|
E.5.2 | Secondary end point(s) |
To determine whether subsequent detection of HCV RNA in subjects who relapse following SVR represents the re-emergence of pre-existing virus, the development of resistance mutations, or re-infection. |
Determinar si la posterior detección de ARN del VHC en sujetos que presenten recidiva después de la RVS supone la reaparición del virus preexistente, el desarrollo de mutaciones de resistencia o una nueva infección. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The proportion of subjects with detectable HCV RNA due to re-emergence of pre-existing virus through Week 240;
The proportion of subjects with detectable HCV resistance mutations through Week 240.
The proportion of subjects with detectable HCV RNA due to re-infection through Week 240. |
La proporción de sujetos con ARN del VHC detectable a causa de la reaparición del virus preexistente hasta la semana 240;
La proporción de sujetos con mutaciones de resistencia del VHC detectables hasta la semana 240;
La proporción de sujetos con ARN del VHC detectable a causa de una nueva infección hasta la semana 240. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Observational study |
Estudio observacional |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 75 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
France |
Germany |
Italy |
New Zealand |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |